Aytu Biopharma (AYTU) Capital Expenditures Growth (1y) (2016 - 2025)
Aytu Biopharma (AYTU) Capital Expenditures Growth (1y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.15 Bn | 87.28 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.49 Bn | 30.55 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.50 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.20 Bn | 21.05 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.58 Bn | 12.15 Bn | 785.00 Mn | -21.54% |
| 10 | Aytu Biopharma | 22.91 Mn | -3.80 Mn | 7.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 183.33% |
| Jun 30, 2025 | -94.83% |
| Jun 30, 2021 | -123.21% |
| Jun 30, 2020 | -1,429.09% |
| Mar 31, 2020 | 282.39% |
| Dec 31, 2019 | 466.80% |
| Mar 31, 2019 | -1,284.02% |
| Mar 31, 2018 | -91.13% |
| Mar 31, 2017 | 309.59% |
| Dec 31, 2016 | -184.28% |